Regulatory news


News

Redwood Pharma AB (publ) Quarterly report January–June 2021

Redwood Pharma will receive approximately SEK 34.2 million through a heavily oversubscribed rights issue

Redwood Pharma announces intention to move to Nasdaq First North Growth Market stock exchange

2020


Redwood Pharma launches new development program for mild dry eye based on its proprietary IntelliGel platform

Quarterly Report January–June 2020

New patent for the use of estrogens in the treatment of DED to be issued in the US

Redwood Pharma secures bridge financing and issues warrants

Quarterly report January – March 2020

RP101 Phase II clinical results

Redwood Pharma AB (publ) Year-end report 2019

Patent to be granted in China regarding IntelliGel

2019


Redwood Pharma AB Quarterly Report January – September 2019

Last patient completes treatment in RP101 Phase II clinical trial

Last patient recruited in Redwood Pharma Phase II trial

Update regarding financial situation

Update regarding RP101 Phase II trial

First patient treated in Redwood Pharma Phase II study

Redwood Pharma receives its third and last national approval

2018


Redwood Pharma receives approval from another drug authority – the Austrian

Redwood Pharma initiates clinical trial

New patent for IntelliGel on the way in the EU

Interim Report January – June 2018

Redwood Pharma has submitted an application for the start of clinical trial

Redwood Pharma’s new rights issue oversubscribed

Redwood Pharma to execute New Rights Issue and takes important step in securing further financing

Redwood Pharma acquires intellectual property rights

Asian Pharmaceutical Firm to Evaluate IntelliGel®

Positive meeting with Medical Products Agency prior to clinical Phase II trial

Additional US patent to be granted regarding IntelliGel

2017


Redwood Pharma starts production of RP101 for clinical trials

Toxicology and Safety Studies are Successfully Completed

Redwood Pharma enters into agreement with CRO for clinical trial

Redwood Pharma begins production of active ingredient in RP101 for Phase II studies

Redwood Pharma initiates toxicological safety studies

New US patent approved

Redwood Pharma AB (publ) End of Year Report 2016

Eye expert to support Redwood Pharma

Redwood Pharma has developed a process for manufacture of the drug RP101 for coming safety studies

2016


Redwood Pharma raises SEK 6.6 million in private placement

Latest presentation

Aktiedagen Lund January 27 2021


Latest report